BACKGROUND AND PURPOSE: A change in acute-to-chronic lesion volume has been proposed as a biomarker for stroke therapies. The objectives of this study were to determine the magnitude of lesion volume change after standard treatment with tissue plasminogen activator and to determine whether specific volume change thresholds can discriminate clinical responders from nonresponders. METHODS: We measured lesion volume on diffusion weighted at baseline and on 90-day fluid attenuated inversion recovery MRI and scored 3-month modified Rankin Scale in consecutive patients treated with tissue plasminogen activator. We identified variables associated with excellent (modified Rankin Scale 0 to 1) and independent (modified Rankin Scale 0 to 2) outcomes. RESULTS: We included 53 patients (mean age 69 years, median baseline National Institutes of Health Stroke Scale score 7). The mean acute-to-chronic lesion volume increase was 11.7 (+/-7.7) cm(3). In 23 patients, the chronic lesion was smaller than the baseline lesion. At 3 months, 32 patients had an excellent clinical outcome. Dichotomous volume change variables associated with outcome included decrease in volume >or=30% (P=0.004) and volume increase >or=5 cm(3) (P=0.002). CONCLUSIONS: In patients given standard tissue plasminogen activator therapy, changes in lesion volume are associated with clinical outcome, and threshold lesion volumes can differentiate excellent and poor outcome, suggesting these as a potential marker of outcome.
BACKGROUND AND PURPOSE: A change in acute-to-chronic lesion volume has been proposed as a biomarker for stroke therapies. The objectives of this study were to determine the magnitude of lesion volume change after standard treatment with tissue plasminogen activator and to determine whether specific volume change thresholds can discriminate clinical responders from nonresponders. METHODS: We measured lesion volume on diffusion weighted at baseline and on 90-day fluid attenuated inversion recovery MRI and scored 3-month modified Rankin Scale in consecutive patients treated with tissue plasminogen activator. We identified variables associated with excellent (modified Rankin Scale 0 to 1) and independent (modified Rankin Scale 0 to 2) outcomes. RESULTS: We included 53 patients (mean age 69 years, median baseline National Institutes of Health Stroke Scale score 7). The mean acute-to-chronic lesion volume increase was 11.7 (+/-7.7) cm(3). In 23 patients, the chronic lesion was smaller than the baseline lesion. At 3 months, 32 patients had an excellent clinical outcome. Dichotomous volume change variables associated with outcome included decrease in volume >or=30% (P=0.004) and volume increase >or=5 cm(3) (P=0.002). CONCLUSIONS: In patients given standard tissue plasminogen activator therapy, changes in lesion volume are associated with clinical outcome, and threshold lesion volumes can differentiate excellent and poor outcome, suggesting these as a potential marker of outcome.
Authors: Steven Warach; David Kaufman; David Chiu; Thomas Devlin; Marie Luby; Ajaz Rashid; Linda Clayton; Markku Kaste; Kennedy R Lees; Ralph Sacco; Marc Fisher Journal: Cerebrovasc Dis Date: 2005-12-09 Impact factor: 2.762
Authors: Anthony J Furlan; Dirk Eyding; Gregory W Albers; Yasir Al-Rawi; Kennedy R Lees; Howard A Rowley; Christian Sachara; Mariola Soehngen; Steven Warach; Werner Hacke Journal: Stroke Date: 2006-03-30 Impact factor: 7.914
Authors: Mark W Parsons; P Alan Barber; Jonathon Chalk; David G Darby; Stephen Rose; Patricia M Desmond; Richard P Gerraty; Brian M Tress; Peter M Wright; Geoffrey A Donnan; Stephen M Davis Journal: Ann Neurol Date: 2002-01 Impact factor: 10.422
Authors: Werner Hacke; Greg Albers; Yasir Al-Rawi; Julien Bogousslavsky; Antonio Davalos; Michael Eliasziw; Michael Fischer; Anthony Furlan; Markku Kaste; Kennedy R Lees; Mariola Soehngen; Steven Warach Journal: Stroke Date: 2004-11-29 Impact factor: 7.914
Authors: Nina M Menezes; Hakan Ay; Ming Wang Zhu; Chloe J Lopez; Aneesh B Singhal; Jari O Karonen; Hannu J Aronen; Yawu Liu; Juho Nuutinen; Walter J Koroshetz; A Gregory Sorensen Journal: Stroke Date: 2006-11-22 Impact factor: 7.914
Authors: Julio A Chalela; Dong-Wha Kang; Marie Luby; Mustapha Ezzeddine; Lawrence L Latour; Jason W Todd; Billy Dunn; Steven Warach Journal: Ann Neurol Date: 2004-01 Impact factor: 10.422
Authors: T Tourdias; P Renou; I Sibon; J Asselineau; L Bracoud; M Dumoulin; F Rouanet; J M Orgogozo; V Dousset Journal: AJNR Am J Neuroradiol Date: 2010-10-21 Impact factor: 3.825
Authors: Hyun-Joo Park; Andre G Machado; Jessica Cooperrider; Havan Truong-Furmaga; Matthew Johnson; Vibhuti Krishna; Zhihong Chen; John T Gale Journal: J Neurosci Methods Date: 2012-12-20 Impact factor: 2.390
Authors: Eckhard Schlemm; Thies Ingwersen; Alina Königsberg; Florent Boutitie; Martin Ebinger; Matthias Endres; Jochen B Fiebach; Jens Fiehler; Ivana Galinovic; Robin Lemmens; Keith W Muir; Norbert Nighoghossian; Salvador Pedraza; Josep Puig; Claus Z Simonsen; Vincent Thijs; Anke Wouters; Christian Gerloff; Götz Thomalla; Bastian Cheng Journal: Nat Commun Date: 2021-05-10 Impact factor: 14.919